"Novo Nordisk A/S (NVO) is a Danish pharmaceutical company that focuses on diabetes care and biopharmaceuticals," notes Nicholas Vardy.

The editor of the Global Bull Market Alert explains, "Novo Nordisk is a quiet giant, employing 30,000 people in 76 countries; we think investors could double their money with this profit machine.

"More than 200 million people worldwide suffer from some form of diabetes. Patients with type 1 (juvenile) diabetes can't make insulin at all and need to inject it their whole lives.

Analyst Upgrades

• Xilinx (XLNX) to buy from hold at Auriga.
• Orion Energy (OESX) to buy from neutral at Roth Capital.
• Goodyear Tire (GT) to buy from fair value at CRT Capital.
• RadioShack (RSH) to neutral from underperform at Wedbush.
• Novo Nordisk (NVO) to buy from neutral at Goldman.

Analyst Upgrades

• JPMorgan upgraded Dollar Tree (DLTR) to neutral from underweight and $48 price target.
• Credit Suisse upgraded Time Warner Cable (TWC) to outperform from neutral and raised its price target to $70 from $59, citing growth in wireline HST demand.
• Needham upgraded NetScout (NTCT) to buy from hold with a $29 price target, citing channel checks that indicate industry spending on network monitoring software may be improving.
• Nstar (NST) was upgraded to buy from neutral at BofA/Merrill.
• Novo Nordisk (NVO) was upgraded to hold from sell at Societe Generale.
• Air France-KLM (AFLYY) was upgraded to neutral from underperform at Credit Suisse.

Analyst Upgrades

• FBR Capital upgraded Digital River (DRIV) to outperform from market perform on expectations the company's business activity is improving. The firm raised its price target for shares to $36 from $25.
• Cowen upgraded Carpenter Technology (CRS) to outperform from neutral, citing expectations for a restocking turnaround for the upgrade.
• Och-Ziff Capital (OZM) was upgraded to outperform from market perform at William Blair.
• Wellpoint (WLP) was upgraded to outperform from market perform at BMO Capital.
• Kohlberg Capital (KCAP) was upgraded to hold from sell at Stifel Nicolaus.

Analyst Upgrades

• RBC Capital upgraded FMC Technologies (FMC) to outperform from sector perform. The firm upgraded shares based on expectations that subsea order flow and backlog will be significantly higher than previous forecasts. The firm has a $70 target on shares.
• Citigroup upgraded ONEOK Partners LP (OKS) to buy from hold due to valuation and maintains a $65 price target on the stock.
• Needham upgraded Autodesk (ADSK) to buy from hold following the Q4 report and guidance. The firm has a $31 target on the stock.
• Morgan Stanley upgraded Under Armour (UA) to equal weight from underweight, citing valuation. The firm raised its target to $27 from $23.
• EOG Resources (EOG) was upgraded to buy from neutral at Goldman.
• FPL Group (FPL) was upgraded to outperform from neutral at Credit Suisse.
• Novo Nordisk (NVO) was upgraded to buy from hold at Jefferies.

Analyst Upgrades

• Jefferies upgraded Citrix Systems (CTXS) to buy from hold and raised its target to $48 from $43, citing VMware's (VMW) strong Q4 report and survey results that indicate continued strength for Citrix.
• Citigroup upgraded Amylin Pharmaceuticals (AMLN) to buy from hold on confidence the company's LAR drug will be approved following the approval of Novo Nordisk's (NVO) Victoza. Citi raised its target price for Amylin shares to $27 from $4.
• Baird upgraded Texas Instruments (TXN) to outperform from neutral and raised its target to $30 from $28. The firm believes it is too early to take profits in Texas Instruments and notes that checks continue to indicate a continued recovery in end-demand.
• Lexmark (LXK) was upgraded to overweight from equal weight at Barclays.
• Salix (SLXP) was upgraded to outperform from perform at Oppenheimer.
• Plexus (PLXS) was lifted to outperform from neutral at Credit Suisse.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• AK Steel Holding Corp. (NYSE: AKS) reported better-than-expected Q3 results but shares fell anyway.
• Baidu Inc. (NASDAQ: BIDU) posted strong Q3 results but shares sold off on a disappointing guidance.
• Burger King Holdings Inc. (NYSE: BKC) said lower Q1 earnings fell short of analysts expectations.
• Dreamworks Animation SKG Inc. (NYSE: DWA) topped Q3 profit and revenue estimates, lifting shares.
• Geron Corp. (NASDAQ: GERN) posted a narrower-than-expected Q3 loss, sending shares sharply higher.
• Honda Motor Co. Ltd. (NYSE: HMC) reported lower Q2 earnings and sales on weak demand for cars.

One would expect generic U.S. drugmaker Mylan (NYSE: MYL) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to $1.26 billion on an operational basis, beating analyst revenue estimates of $1.23 billion. Still, revenue in North America, where most pharmas have been hurting, rose 9.2 percent to $502.5 million, helped by new product launches and increased volume.

On an adjusted basis, Mylan posted better-than-expected third-quarter results on Thursday, reporting an earnings per share of 32 cents -- 5 cents higher than the average estimate of analysts polled by Thomson Reuters I/B/E/S. It seems that just like branded pharmas, Mylan benefited from cost cuts. Still, the world's No. 3 generic drugmaker raised its full-year outlook and said it believes it can continue its current momentum into 2010.

In a review of the pharmaceutical sector, Chuck Carlson selects his favorite International stocks which also offer direct-purchase plans for U.S. investors.

Here's a look at two of these stocks -- United Kingdom-based AstraZeneca (NYSE: AZN) and Denmark-based Novo Nordisk (NYSE: NVO) -- from his The DRIP Investor, a newsletter focused on long-term, high quality investments.

"AstraZeneca is a leading pharmaceutical firm. The company boasts a portfolio that includes 11 products that generate more than $1 billion each in annual sales.

Analyst upgrades:

• Merriman upgraded shares of Akamai (NASDAQ:AKAM) to Buy from Neutral as they believe consensus expectations are now realistic and already reflect macro headwinds. Merriman also thinks the company's cost reductions could generate upside to EPS estimates.
  
• JP Morgan upgraded Novo Nordisk (NYSE:NVO) to Overweight from Neutral on expectations the company's diabetes drug will gain U.S. approval.
  
• Credit Suisse upgraded Pfizer (NYSE:PFE) to Outperform from Neutral and raised their target to $20 from $19 citing the merits of the Wyeth (WYE) deal and valuation.
• Quality Systems (NASDAQ:QSII) was upgraded to Buy from Neutral at Piper Jaffray.
  
• Parexel (NASDAQ:PRXL) was raised to Outperform from Market Perform at Wachovia.
  
• Ferro (NYSE:FOE) was upgraded at KeyBanc to Hold from Underweight.

Analyst upgrades:

• Merrill upgraded shares of AstraZeneca (NYSE: AZN) to Neutral from Underperform to reflect the company's pipeline momentum and lack of negative catalysts.
  
• Keefe Bruyette upgraded Deutsche Bank (NYSE: DB) to Outperform from Market Perform on valuation as they believe DB should trade at a higher multiple.
• Royal Dutch Shell (NYSE: RDS.A) was raised at HSBC to Overweight from Neutral.
• American International (NYSE: AIG) was upgraded to Buy from Neutral at UBS.

• Merrill cut Novo Nordisk (NYSE: NVO) to Underperform from Neutral as the firm sees better opportunities elsewhere in the sector.
  
• Merriman downgraded Rackable Systems (NASDAQ: RACK) to Neutral from Buy following the company's mixed Q2 results to reflect its customer concentration and fluctuating margins.
• Janus Capital (NYSE: JNS) was downgraded at JP Morgan to Underweight from Neutral.
  
• Fortress (NYSE: FIG) was cut to Sell from Hold at Citigroup.

• UBS believes Apple (NASDAQ: AAPL) has a competitive advantage and their checks indicate new Macs, new iPhone colors and potentially new iPods may come early on in the second half of 2008. The firm initiated shares with a Buy rating and $195 target. UBS also initiated Dell Inc. (NASDAQ: DELL) and Hewlett-Packard (NYSE: HPQ) at Neutral.
• KeyBanc initiated Bed Bath & Beyond (NASDAQ: BBBY) with an Underweight rating and $25 target based on slowing core growth at Bed Bath and likely margin erosion from the ramp in growth at Christmas Tree Shops and buybuy Baby.
• Infineon (NYSE: IFX) was initiated with a Buy rating at Deutsche Bank.

MOST NOTEWORTHY:

• Keefe Bruyette upgraded shares of Webster Financial (NYSE: WBS) to Outperform from Market Perform on valuation as they feel the company is adequately capitalized and in a position to withstand the weakening credit markets.
  
• JP Morgan upgraded Eaton (NYSE: ETN) to Overweight from Neutral citing bullish management comments at its conference last week.
  
• Piper upgraded Macrovision (NASDAQ: MVSN) to Buy from Neutral citing the closure of the Gemstar deal.

• Lehman upgraded U.S. stocks to Overweight from Underweight.
  
• Goldman added Hess Corp (NYSE: HES) and Mosaic (NYSE: MOS) to its Conviction Buy List.
  
• Novo Nordisk (NYSE: NVO) was raised at HSBC to Neutral from Underweight.
  
• Jefferies upgraded ASM International (NASDAQ: ASMI) to Hold from Underperform.

The fund has some pretty high ideals according to its Web site: "We focus on the economic, environmental, social, and governance risks and opportunities that can materially affect a company's ability to sustain profitability and deliver returns. Our research plays an important role in forming our views on the quality of the business, the quality of management, and valuation."

So how does that translate in the real world? Al Gore isn't providing performance details, according to the Bloomberg story. It's kind of weird for Gore to be so mum considering that its biggest holding Novo Nordisk (NYSE: NVO) is up more than 60% over the past year in U.S. trading.

MOST NOTEWORTHY:

• B. Riley downgraded shares of World Wrestling Entertainment (NYSE: WWE) to Neutral from Buy on valuation with the stock only 1% below their target price. However, B. Riley admits shares may move higher during the next 30-35 days, due to the upcoming WrestleMania event in Orlando, FL.
  
• Novo Nordisk (NYSE: NVO) was downgraded to Neutral from Buy at Merrill on valuation and a lack of near-term catalysts; shares were also lowered to Peer Perform from Outperform at Bear Stearns.
  
• ING lowered Nestle (OTC: NSRGY) to Hold from Buy as they expect organic growth to slow in 2008.

• Banc of America downgraded Paychex (NASDAQ: PAYX) to Neutral from Buy.
  
• HSBC downgraded Repsol SA (NYSE: REP) to Neutral from Overweight.
  
• Del Monte Foods (NYSE: DLM) was downgraded to Market Perform from Outperform at Wachovia.